Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alizapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 12/20 | 0.68 |
| ▸ | DRD3 | P35462 | 7/20 | 0.68 |
| ▸ | DRD4 | P21917 | 6/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alizapride SCHEMBL1649436 | 1.00 | DRD2 (0.68) | DRD2DRD3DRD4CA12CA1 | |
| Alizapride SCHEMBL48936 | 0.88 | DRD2 (0.65) | DRD2DRD3DRD4CA12CA1 | |
| Alizapride SCHEMBL30089955 | 0.88 | DRD2 (0.65) | DRD2DRD3DRD4CA12CA1 | |
| Alizapride SCHEMBL3764712 | 0.87 | DRD2 (0.64) | DRD2DRD3DRD4CA12CA1 | |
| Alizapride SCHEMBL18613208 | 0.87 | DRD2 (0.63) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL8211543 | 0.84 | DRD2 (0.64) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL9835471 | 0.82 | DRD2 (0.69) | DRD2DRD3DRD4CA12CA1 | |
| Alizapride SCHEMBL461456 | 0.81 | DRD2 (0.57) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL14962446 | 0.79 | DRD2 (0.56) | DRD2DRD3DRD4CA12CA1 | |
| SCHEMBL11075409 | 0.78 | DRD2 (0.64) | DRD2DRD3DRD4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3924 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658240-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | Therakind Limited (GB) | 2025-12-10 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024161129-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | THERAKIND LIMITED (GB) | 2024-08-08 | — | — | WO | claimed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000051563-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING A BENZAMIDE AND AT LEAST AN ABSORPTION PROMOTER | SANOFI-SYNTHELABO (FR) | 2000-09-08 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000023045-A1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI-SYNTHELABO (FR) | 2000-04-27 | — | — | WO | claimed |
| US-5684018-A | Acyloxyisopropyl carbamates as prodrugs for amine drugs | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | claimed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0526862-B1 | Solid pharmaceutical compositions for oral administration with prolonged gastric residence | VECTORPHARMA INT (IT) | 1996-02-14 | — | — | EP | claimed |
| EP-0526862-A1 | Solid pharmaceutical compositions for oral administration with prolonged gastric residence | VECTORPHARMA INTERNATIONAL S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| US-4880632-A | DZ RECEPTORS DOPAMINE ANTAGONIST, BENZAMIDES | THE UNITED STATES OF AMERICA (US) | 1989-11-14 | — | — | US | claimed |